-Livemint The development economist on the Modi government's initiatives and his stand on them, and MGNREGS The Narendra Modi-led government should consider replacing inefficient subsidies with a basic monthly income for all citizens, says Pranab Bardhan , emeritus professor of economics at the University of California at Berkeley. Bardhan, who recently sparred with economists Jagdish Bhagwati and Arvind Panagariya in a debate over the Mahatma Gandhi National Rural Employment Guarantee Scheme (MGNREGS),...

-The Hindu Business Line   Wants PAN used in payments over ₹1 lakh, cap on amount of cash a person can keep Income Tax authorities have traced about ₹4,500 crore in undisclosed money in bank accounts overseas, a Special Investigation Team (SIT) probing the matter said in its second report to the Supreme Court. The report, released on Friday, said investigations are pending in 33 cases involving an amount of ₹14,957.95 crore, and that...

-The Tribune BARC reports toxic metals in fertilisers as firms avoid costly decontamination process Bathinda (Punjab): The Bhabha Atomic Research Centre (BARC) has found high uranium content in diammonium phosphate and single superphosphate fertilisers that do not undergo the costlier decontamination process during production. The conclusion was reached after testing of soil and fertiliser samples. The Environmental Assessment Division of BARC sent a report on samples of DAP (diammonium phosphate) and single superphosphate...

-Business Standard Domestic regulators need to be stricter about quality violations to protect both Indian pharma exports as well as the country's image Even as major Indian drug companies continue to make news for impurities in the medicines they make and faulty - or if the USFDA is to be believed, falsified - data that many generate after testing of samples show quality problem, it seems strange that domestic authorities are silent...

-The Telegraph Regulators in several European countries are suspending marketing approval for 25 generic drugs because of concerns over the quality of data from human studies conducted by an Indian contract research company, a French medical safety agency said on Friday. Drug regulators in Belgium, France, Germany and Luxembourg have decided to suspend the marketing authorisation for the generic drugs after they discovered "irregularities" in documents relating to human studies conducted by...